Repligen Stock Price, News & Analysis (NASDAQ:RGEN)

$35.35 -0.21 (-0.59 %)
(As of 12/11/2017 04:00 PM ET)
Previous Close$35.56
Today's Range$35.10 - $36.27
52-Week Range$28.48 - $46.81
Volume258,042 shs
Average Volume324,679 shs
Market Capitalization$1.55 billion
P/E Ratio61.31
Dividend YieldN/A
Beta1.04

About Repligen (NASDAQ:RGEN)

Repligen logoRepligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Receive RGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RGEN
CUSIP75991610
Phone781-250-0111

Debt

Debt-to-Equity RatioN/A
Current Ratio1.95%
Quick Ratio1.63%

Price-To-Earnings

Trailing P/E Ratio61.31
Forward P/E Ratio57.95
P/E Growth2.32

Sales & Book Value

Annual Sales$104.54 million
Price / Sales14.73
Cash Flow$0.60 per share
Price / Cash58.77
Book Value$4.99 per share
Price / Book7.08

Profitability

Trailing EPS$0.59
Net Income$11.68 million
Net Margins16.93%
Return on Equity7.57%
Return on Assets5.19%

Miscellaneous

Employees236
Outstanding Shares43,560,000

Repligen (NASDAQ:RGEN) Frequently Asked Questions

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) released its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.11 by $0.04. The biotechnology company earned $36.58 million during the quarter, compared to analysts' expectations of $35.69 million. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The business's quarterly revenue was up 48.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.08 earnings per share. View Repligen's Earnings History.

When will Repligen make its next earnings announcement?

Repligen is scheduled to release their next quarterly earnings announcement on Tuesday, February, 20th 2018. View Earnings Estimates for Repligen.

What guidance has Repligen issued on next quarter's earnings?

Repligen updated its FY17 earnings guidance on Thursday, November, 9th. The company provided earnings per share (EPS) guidance of $0.60-0.63 for the period, compared to the Thomson Reuters consensus estimate of $0.59. The company issued revenue guidance of $139-142 million, compared to the consensus revenue estimate of $140.72 million.

Where is Repligen's stock going? Where will Repligen's stock price be in 2017?

7 Wall Street analysts have issued 1-year price objectives for Repligen's shares. Their predictions range from $40.00 to $50.00. On average, they anticipate Repligen's share price to reach $44.57 in the next year. View Analyst Ratings for Repligen.

Who are some of Repligen's key competitors?

Who are Repligen's key executives?

Repligen's management team includes the folowing people:

  • Karen A. Dawes, Independent Chairperson of the Board (Age 64)
  • Tony John Hunt, President, Chief Executive Officer, Director (Age 53)
  • Jon K. Snodgres, Chief Financial Officer (Age 51)
  • Howard Benjamin Ph.D., Vice President - Business Development (Age 57)
  • Nicolas M. Barthelemy, Independent Director (Age 51)
  • Glenn L. Cooper M.D., Independent Director (Age 64)
  • John G. Cox, Independent Director (Age 54)
  • Glenn P. Muir, Independent Director (Age 58)
  • Thomas F. Ryan Jr., Independent Director (Age 75)

Who owns Repligen stock?

Repligen's stock is owned by a number of of institutional and retail investors. Top institutional investors include TimesSquare Capital Management LLC (6.79%), Conestoga Capital Advisors LLC (3.89%), Stephens Investment Management Group LLC (2.70%), Dimensional Fund Advisors LP (1.93%), Macquarie Group Ltd. (2.21%) and Palisade Capital Management LLC NJ (1.76%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.

Who sold Repligen stock? Who is selling Repligen stock?

Repligen's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, TimesSquare Capital Management LLC, Wells Fargo & Company MN, Russell Investments Group Ltd., Prudential Financial Inc., Pier Capital LLC, Schroder Investment Management Group and North Star Asset Management Inc.. Company insiders that have sold Repligen company stock in the last year include Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.

Who bought Repligen stock? Who is buying Repligen stock?

Repligen's stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Conestoga Capital Advisors LLC, Mackenzie Financial Corp, Perceptive Advisors LLC, Assenagon Asset Management S.A., Kornitzer Capital Management Inc. KS, Stephens Investment Management Group LLC and American Century Companies Inc.. View Insider Buying and Selling for Repligen.

How do I buy Repligen stock?

Shares of Repligen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Repligen's stock price today?

One share of Repligen stock can currently be purchased for approximately $35.35.

How big of a company is Repligen?

Repligen has a market capitalization of $1.55 billion and generates $104.54 million in revenue each year. The biotechnology company earns $11.68 million in net income (profit) each year or $0.59 on an earnings per share basis. Repligen employs 236 workers across the globe.

How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]


MarketBeat Community Rating for Repligen (RGEN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  229
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Repligen (NASDAQ:RGEN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.752.502.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $44.57$46.00$41.00$35.67
Price Target Upside: 28.89% upside26.83% upside2.77% downside1.73% upside

Repligen (NASDAQ:RGEN) Consensus Price Target History

Price Target History for Repligen (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2017CitigroupInitiated CoverageBuy -> Buy$45.00MediumView Rating Details
12/5/2017J P Morgan Chase & CoInitiated CoverageOverweight -> Overweight$42.00HighView Rating Details
11/13/2017CL KingInitiated CoverageBuy -> Buy$41.00N/AView Rating Details
10/19/2017Jefferies GroupReiterated RatingHold$40.00N/AView Rating Details
10/2/2017First AnalysisUpgradeEqual Weight -> Overweight$47.00MediumView Rating Details
9/26/2017StephensReiterated RatingOverweight$50.00HighView Rating Details
7/21/2017William BlairInitiated CoverageOutperform -> OutperformLowView Rating Details
6/23/2017Janney Montgomery ScottBoost Price Target$42.00 -> $47.00HighView Rating Details
2/22/2016Craig HallumInitiated CoverageBuyN/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Repligen (NASDAQ:RGEN) Earnings History and Estimates Chart

Earnings by Quarter for Repligen (NASDAQ:RGEN)

Repligen (NASDAQ RGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018$0.12N/AView Earnings Details
11/9/2017Q3 2017$0.11$0.15$35.69 million$36.58 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.15$0.20$31.72 million$32.40 millionViewListenView Earnings Details
5/4/20173/31/2017$0.13$0.15$29.28 million$30.59 millionViewListenView Earnings Details
2/22/2017Q416$0.07$0.08$24.05 million$25.60 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$24.39 million$24.70 millionViewN/AView Earnings Details
8/4/2016Q216$0.13$0.16$24.75 million$29.20 millionViewN/AView Earnings Details
5/5/2016Q116$0.10$0.12$22.54 million$25.10 millionViewN/AView Earnings Details
2/25/2016Q415$0.07$0.07$19.84 million$21.40 millionViewListenView Earnings Details
11/5/2015Q315$0.08$0.08$20.50 million$19.80 millionViewN/AView Earnings Details
8/6/2015Q215$0.08$0.11$20.05 million$21.50 millionViewN/AView Earnings Details
5/7/2015Q115$0.07$0.09$18.20 million$20.82 millionViewN/AView Earnings Details
3/13/2015Q414$0.04($0.01)$14.70 million$15.40 millionViewN/AView Earnings Details
11/6/2014Q314$0.04$0.04$15.60 million$15.30 millionViewN/AView Earnings Details
8/11/2014Q114$0.06$0.09$14.90 million$15.60 millionViewN/AView Earnings Details
5/8/2014Q1$0.07$0.13$15.14 million$16.33 millionViewListenView Earnings Details
3/6/2014Q413$0.14$0.10$15.88 million$10.40 millionViewListenView Earnings Details
11/7/2013Q313$0.13$0.18$16.27 million$18.80 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.10$0.14$15.97 million$17.50 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.07$12.82 million$16.46 millionViewListenView Earnings Details
11/8/2012Q312$0.06$8.63 million$15.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Repligen (NASDAQ:RGEN) Earnings Estimates

2017 EPS Consensus Estimate: $0.54
2018 EPS Consensus Estimate: $0.70
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.13$0.13$0.13
Q2 20173$0.15$0.17$0.16
Q3 20174$0.09$0.15$0.13
Q4 20174$0.12$0.13$0.13
Q1 20183$0.16$0.17$0.16
Q2 20183$0.19$0.20$0.19
Q3 20183$0.15$0.20$0.18
Q4 20182$0.16$0.18$0.17
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Repligen (NASDAQ:RGEN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Repligen (NASDAQ RGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.50%
Institutional Ownership Percentage: 83.31%
Insider Trades by Quarter for Repligen (NASDAQ:RGEN)
Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Repligen (NASDAQ RGEN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/21/2017Karen A DawesDirectorSell2,521$34.12$86,016.52View SEC Filing  
3/20/2017Howard BenjaminVPSell12,216$34.62$422,917.92View SEC Filing  
3/20/2017Thomas F Ryan JrDirectorSell4,000$34.83$139,320.00View SEC Filing  
3/17/2017Jon SnodgresCFOSell1,909$34.91$66,643.19View SEC Filing  
11/28/2016Anthony HuntCEOSell5,000$33.12$165,600.00View SEC Filing  
9/14/2016Thomas F Ryan JrDirectorSell2,700$32.58$87,966.00View SEC Filing  
6/30/2016Thomas F Ryan JrDirectorSell5,000$26.60$133,000.00View SEC Filing  
6/28/2016Thomas F Ryan JrDirectorSell10,000$24.59$245,900.00View SEC Filing  
5/11/2016Howard BenjaminVPSell2,889$26.72$77,194.08View SEC Filing  
6/9/2015Howard BenjaminVPSell35,000$38.14$1,334,900.00View SEC Filing  
5/11/2015Walter C HerlihyCEOSell104,569$37.94$3,967,347.86View SEC Filing  
5/8/2015Thomas F Ryan JrDirectorSell20,000$37.19$743,800.00View SEC Filing  
3/23/2015Walter C HerlihyCEOSell24,536$31.78$779,754.08View SEC Filing  
3/19/2015James R RuscheSVPSell14,650$33.30$487,845.00View SEC Filing  
3/19/2015Thomas F Ryan JrDirectorSell10,000$32.62$326,200.00View SEC Filing  
3/19/2015Walter C HerlihyCEOSell49,695$33.08$1,643,910.60View SEC Filing  
3/18/2015Howard BenjaminVPSell15,795$32.63$515,390.85View SEC Filing  
11/19/2014Walter C HerlihyCEOSell51,386$23.43$1,203,973.98View SEC Filing  
11/13/2014Thomas F Ryan JrDirectorSell10,000$23.81$238,100.00View SEC Filing  
11/11/2014Howard BenjaminVPSell30,000$23.56$706,800.00View SEC Filing  
11/10/2014Michael A GriffithDirectorSell23,342$22.90$534,531.80View SEC Filing  
8/13/2014Howard BenjaminVPSell40,000$20.34$813,600.00View SEC Filing  
6/27/2014Thomas F Ryan JrDirectorSell10,000$22.41$224,100.00View SEC Filing  
6/24/2014Thomas F Ryan JrDirectorSell10,000$21.78$217,800.00View SEC Filing  
6/11/2014Walter C HerlihyCEOSell60,335$20.11$1,213,336.85View SEC Filing  
6/9/2014James R RuscheSVPSell30,000$20.19$605,700.00View SEC Filing  
6/6/2014Daniel P WittSVPSell47,709$20.56$980,897.04View SEC Filing  
4/15/2014Daniel P WittSVPBuy10,000$3.05$30,500.00View SEC Filing  
8/8/2013James R RuscheSVPSell30,000$10.01$300,300.00View SEC Filing  
6/21/2013Karen A DawesDirectorBuy1,000$7.70$7,700.00View SEC Filing  
5/17/2013Thomas F Ryan JrDirectorSell21,000$8.97$188,370.00View SEC Filing  
5/15/2013Thomas F Ryan JrDirectorSell86,039$9.01$775,211.39View SEC Filing  
5/15/2013Walter C HerlihyCEOSell40,000$8.97$358,800.00View SEC Filing  
9/21/2012Glenn L Md CooperDirectorBuy10,000$6.09$60,900.00View SEC Filing  
8/16/2012Michael A GriffithDirectorBuy2,000$4.88$9,760.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Repligen (NASDAQ RGEN) News Headlines

Source:
DateHeadline
Repligen (RGEN) Coverage Initiated by Analysts at CitigroupRepligen (RGEN) Coverage Initiated by Analysts at Citigroup
www.americanbankingnews.com - December 8 at 10:28 PM
Repligen Co. (RGEN) Receives Consensus Rating of "Buy" from BrokeragesRepligen Co. (RGEN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 8 at 4:22 AM
 Analysts Expect Repligen Co. (RGEN) Will Post Quarterly Sales of $41.37 Million Analysts Expect Repligen Co. (RGEN) Will Post Quarterly Sales of $41.37 Million
www.americanbankingnews.com - December 6 at 2:18 AM
Repligen (RGEN) Earns Overweight Rating from Analysts at J P Morgan Chase & CoRepligen (RGEN) Earns Overweight Rating from Analysts at J P Morgan Chase & Co
www.americanbankingnews.com - December 5 at 5:12 PM
JPMorgan Starts Repligen (RGEN) at Overweight, "The Best Pure Play" - StreetInsider.comJPMorgan Starts Repligen (RGEN) at Overweight, "The Best Pure Play" - StreetInsider.com
www.streetinsider.com - December 5 at 7:10 AM
$0.12 EPS Expected for Repligen Co. (RGEN) This Quarter$0.12 EPS Expected for Repligen Co. (RGEN) This Quarter
www.americanbankingnews.com - December 4 at 9:30 PM
3 Bioeconomy Stocks That Have a Killer Advantage3 Bioeconomy Stocks That Have a Killer Advantage
finance.yahoo.com - November 30 at 7:23 AM
Repligen Corporation (RGEN) Coverage Initiated at CL KingRepligen Corporation (RGEN) Coverage Initiated at CL King
www.americanbankingnews.com - November 27 at 12:34 AM
First Analysis Research Analysts Lift Earnings Estimates for Repligen Corporation (RGEN)First Analysis Research Analysts Lift Earnings Estimates for Repligen Corporation (RGEN)
www.americanbankingnews.com - November 22 at 6:20 AM
TheStreet Downgrades Repligen Corporation (RGEN) to CTheStreet Downgrades Repligen Corporation (RGEN) to C
www.americanbankingnews.com - November 19 at 7:37 PM
Equities Analysts Offer Predictions for Repligen Corporations FY2017 Earnings (RGEN)Equities Analysts Offer Predictions for Repligen Corporation's FY2017 Earnings (RGEN)
www.americanbankingnews.com - November 17 at 8:08 PM
$0.13 Earnings Per Share Expected for Repligen Corporation (RGEN) This Quarter$0.13 Earnings Per Share Expected for Repligen Corporation (RGEN) This Quarter
www.americanbankingnews.com - November 16 at 9:28 AM
Repligen Corporation (RGEN) Given Average Recommendation of "Buy" by AnalystsRepligen Corporation (RGEN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 13 at 2:12 AM
Edited Transcript of RGEN earnings conference call or presentation 9-Nov-17 1:30pm GMTEdited Transcript of RGEN earnings conference call or presentation 9-Nov-17 1:30pm GMT
finance.yahoo.com - November 12 at 12:16 PM
Repligen Corporation (RGEN) Announces  Earnings ResultsRepligen Corporation (RGEN) Announces Earnings Results
www.americanbankingnews.com - November 9 at 4:52 PM
RSI Alert: Repligen (RGEN) Now OversoldRSI Alert: Repligen (RGEN) Now Oversold
www.nasdaq.com - November 9 at 12:27 PM
Should You Sell Repligen Corporation (RGEN) Before Earnings?Should You Sell Repligen Corporation (RGEN) Before Earnings?
finance.yahoo.com - November 9 at 12:27 PM
Repligen Corporation to Host Earnings CallRepligen Corporation to Host Earnings Call
finance.yahoo.com - November 9 at 12:27 PM
Repligen Reports Third Quarter 2017 Financial ResultsRepligen Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 12:27 PM
Repligen tops Street 3Q forecastsRepligen tops Street 3Q forecasts
finance.yahoo.com - November 9 at 12:27 PM
Repligen Corporation (RGEN) Issues FY17 Earnings GuidanceRepligen Corporation (RGEN) Issues FY17 Earnings Guidance
www.americanbankingnews.com - November 9 at 9:22 AM
Repligen Extends Long Term Supply Agreement with Purolite for Protein A LigandsRepligen Extends Long Term Supply Agreement with Purolite for Protein A Ligands
finance.yahoo.com - November 7 at 9:33 AM
Repligen Corporation (RGEN) Set to Announce Quarterly Earnings on ThursdayRepligen Corporation (RGEN) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - November 2 at 4:38 AM
Purolite Selects Repligens Market-Leading OPUS® Pre-Packed Columns - PR Newswire (press release)Purolite Selects Repligen's Market-Leading OPUS® Pre-Packed Columns - PR Newswire (press release)
www.prnewswire.com - November 1 at 3:41 PM
Repligen to Report Third Quarter 2017 Financial ResultsRepligen to Report Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 3:41 PM
ETFs with exposure to Repligen Corp. : November 1, 2017ETFs with exposure to Repligen Corp. : November 1, 2017
finance.yahoo.com - November 1 at 3:41 PM
Purolite Selects Repligens Market-Leading OPUS® Pre-Packed ColumnsPurolite Selects Repligen's Market-Leading OPUS® Pre-Packed Columns
finance.yahoo.com - November 1 at 8:04 AM
Stocks With Rising Relative Strength: RepligenStocks With Rising Relative Strength: Repligen
finance.yahoo.com - November 1 at 8:04 AM
Head to Head Contrast: Mallinckrodt PLC (MNK) & Repligen Corporation (RGEN)Head to Head Contrast: Mallinckrodt PLC (MNK) & Repligen Corporation (RGEN)
www.americanbankingnews.com - October 30 at 12:58 AM
Repligen Corporation (RGEN) Expected to Post Earnings of $0.11 Per ShareRepligen Corporation (RGEN) Expected to Post Earnings of $0.11 Per Share
www.americanbankingnews.com - October 27 at 3:06 AM
Head to Head Contrast: Macrocure (MCUR) versus Repligen Corporation (RGEN)Head to Head Contrast: Macrocure (MCUR) versus Repligen Corporation (RGEN)
www.americanbankingnews.com - October 26 at 5:35 PM
Repligen Corporation (RGEN) Set to Announce Quarterly Earnings on WednesdayRepligen Corporation (RGEN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 7:49 AM
Repligen Corporation (RGEN) Rating Reiterated by Jefferies Group LLCRepligen Corporation (RGEN) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - October 22 at 9:44 PM
RGEN Crosses Above Key Moving Average LevelRGEN Crosses Above Key Moving Average Level
www.nasdaq.com - October 20 at 3:58 PM
ETFs with exposure to Repligen Corp. : October 20, 2017ETFs with exposure to Repligen Corp. : October 20, 2017
finance.yahoo.com - October 20 at 3:57 PM
Repligen Corporation (RGEN) Given Consensus Rating of "Buy" by BrokeragesRepligen Corporation (RGEN) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 19 at 2:34 AM
Contrasting Advanced Accelerator Applications (AAAP) and Repligen Corporation (RGEN)Contrasting Advanced Accelerator Applications (AAAP) and Repligen Corporation (RGEN)
www.americanbankingnews.com - October 18 at 4:24 PM
Critical Survey: Repligen Corporation (RGEN) versus TherapeuticsMD (TXMD)Critical Survey: Repligen Corporation (RGEN) versus TherapeuticsMD (TXMD)
www.americanbankingnews.com - October 15 at 9:00 AM
Financial Comparison: Mallinckrodt PLC (MNK) vs. Repligen Corporation (RGEN)Financial Comparison: Mallinckrodt PLC (MNK) vs. Repligen Corporation (RGEN)
www.americanbankingnews.com - October 12 at 4:24 PM
Repligen Corporation (RGEN) Cut to "Hold" at Zacks Investment ResearchRepligen Corporation (RGEN) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 11 at 10:18 AM
Head to Head Review: Advanced Accelerator Applications (AAAP) & Repligen Corporation (RGEN)Head to Head Review: Advanced Accelerator Applications (AAAP) & Repligen Corporation (RGEN)
www.americanbankingnews.com - October 11 at 12:30 AM
ETFs with exposure to Repligen Corp. : October 9, 2017ETFs with exposure to Repligen Corp. : October 9, 2017
finance.yahoo.com - October 10 at 6:23 AM
Repligen Corporation (RGEN) versus Its Peers Head-To-Head ReviewRepligen Corporation (RGEN) versus Its Peers Head-To-Head Review
www.americanbankingnews.com - October 9 at 4:12 PM
Repligen Corporation (RGEN) Upgraded to Buy at Zacks Investment ResearchRepligen Corporation (RGEN) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - October 8 at 11:40 AM
Critical Contrast: Assembly Biosciences (ASMB) & Repligen Corporation (RGEN)Critical Contrast: Assembly Biosciences (ASMB) & Repligen Corporation (RGEN)
www.americanbankingnews.com - October 8 at 10:38 AM
$0.11 EPS Expected for Repligen Corporation (RGEN) This Quarter$0.11 EPS Expected for Repligen Corporation (RGEN) This Quarter
www.americanbankingnews.com - October 8 at 12:20 AM
Repligen Corporation (RGEN) to Post FY2020 Earnings of $1.12 Per Share, Jefferies Group ForecastsRepligen Corporation (RGEN) to Post FY2020 Earnings of $1.12 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - October 4 at 4:50 PM
Rockwell Medical (RMTI) vs. Repligen Corporation (RGEN) Head-To-Head AnalysisRockwell Medical (RMTI) vs. Repligen Corporation (RGEN) Head-To-Head Analysis
www.americanbankingnews.com - September 28 at 8:30 PM
Relative Strength Alert For Repligen - NasdaqRelative Strength Alert For Repligen - Nasdaq
www.nasdaq.com - September 27 at 11:15 PM
Notable Two Hundred Day Moving Average Cross - RGENNotable Two Hundred Day Moving Average Cross - RGEN
www.nasdaq.com - September 27 at 6:13 PM

SEC Filings

Repligen (NASDAQ:RGEN) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Repligen (NASDAQ:RGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Repligen (NASDAQ RGEN) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.